Zimmer Biomet reports Q3 adjusted EPS $1.90, consensus $1.86

Core Insights - Zimmer Biomet reported Q3 revenue of $2 billion, slightly below consensus estimates of $2.01 billion, with a notable 5.6% organic revenue growth in the U.S. business driven by the adoption of new products known as the 'Magnificent Seven' [1] - The company is preparing to launch innovative technologies, including the first fully autonomous robot in orthopedics and an iodine-treated hip implant, which is the first of its kind to prevent bacterial adhesion and biofilm formation [1] - While the U.S. performance was strong, it was partially offset by weaknesses in Latin America, Emerging Markets in Europe, and non-core businesses, which emerged late in the quarter and are currently being addressed [1]